A phase 2B study of inhaled Pitrakinra, an IL-4/IL-13 antagonist, successfully identified responder subpopulations of patients with uncontrolled asthma

Category Primary study
JournalAmerican Journal of Respiratory and Critical Care Medicine
Year 2011
This article has no abstract
Epistemonikos ID: 96a3bd0262fafb3b6a7f6daefc5cd3a40f5f159e
First added on: Feb 05, 2025